Patient‐derived xenografts: Practical considerations for preclinical drug testing
Open Access
- 16 April 2025
- journal article
- Published by Wiley in HemaSphere
- Vol. 9 (4) , e70133
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Immune‐deficient MISTRG mice support expansion of leukaemia‐initiating cells in xenograft models of paediatric acute myeloid leukaemiaBritish Journal of Haematology, 2025
- The CD123 antibody–drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemiaHemaSphere, 2025
- PDX models for functional precision oncology and discovery scienceNature Reviews Cancer, 2024
- Lessons learned from 20 years of preclinical testing in pediatric cancersPharmacology & Therapeutics, 2024
- Influence of donor–recipient sex on engraftment of normal and leukemia stem cells in xenotransplantationHemaSphere, 2024
- In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenograftsExperimental Hematology, 2024
- Immunodeficient NBSGW mouse strain allows chemotherapy modeling in AML patient‐derived xenograftsHemaSphere, 2024
- PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft ModelsCancer Research, 2017
- Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse AnalysisCancer Research, 2016
- Humanized NOD-SCID IL2rg –/– mice as a preclinical model for cancer research and its potential use for individualized cancer therapiesCancer Letters, 2014